The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for Mounjaro (tirzepatide). The marketing… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Dovprela. (pretomanid). The marketing… read more.
Caris Life Sciences announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. In… read more.
Cytokinetics, Incorporated announced that Myqorzo (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA)… read more.
Altamira Therapeutics Ltd. announced that its associate company Altamira Medica has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Bentrio nasal spray… read more.
Hansa Biopharma AB announced the submission of a Biologics License Application (BLA) to the FDA for imlifidase. The Company is requesting priority review of the BLA for the… read more.
BD (Becton, Dickinson and Company) announced the launch of the BD Surgiphor Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive… read more.
Abeona Therapeutics Inc. announced the first patient treatment with FDA-approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive… read more.
Guardant Health Inc. announced new data demonstrating that its Guardant Reveal blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months… read more.
Organon announced that it has entered into an agreement with Laborie Medical Technologies Corp., a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA… read more.
Chugai and Renalys Pharma, Inc. announced positive topline results from its Phase III clinical study of sparsentan (RE 021), an orally administered dual endothelin and angiotensin II receptor… read more.
GSK plc announced that the FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
